Skip to main content

Table 1 Baseline demographic, clinical treatment and psychosocial characteristics of participants

From: Comparison of six methods to estimate adherence in an ART-naïve cohort in a resource-poor setting: which best predicts virological and resistance outcomes?

Variable Full cohort With VL at week 16 With VL at week 48
Number: n 230 160 180
Female sex: n (%) 150 (65.2) 108 (67.5) 121 (67.2)
Age in years: mean (SD) 34.5 (9.1) 34.8 (8.9) 35.0 (9.4)
Height (cm): mean (SD) 164.0 (8.6) 164.1 (8.2) 164.0 (8.1)
Weight (kg): median (IQR) 67.3 (57.8–79.6) 67.2 (58.0–80.0) 68.1 (58.7–80.4)
BMI: median (IQR) 24.3 (21.3–29.8) 24.2 (21.5–29.9) 24.6 (21.5–30.7)
WHO stage: n (%)
 1 84 (36.5) 58 (36.3) 73 (40.6)
 2 47 (20.4) 34 (21.3) 39 (21.7)
 3 75 (32.6) 54 (33.8) 51 (28.3)
 4 24 (10.4) 14 (8.8) 17 (9.4)
CD4 count (cells/mm3): median (IQR) 225 (133–287) 229 (132–288) 233 (144–287)
Log HIV-RNA (copies/ml): median (IQR) 4.9 (4.4–5.4) 4.9 (4.4–5.4) 4.8 (4.4–5.4)
NNRTI at start: n (%)
 Efavirenz 228 (99.1) (98)  
 Nevirapine 2 (0.9) 2 (1.2) 2 (1.1)
 NRTI at starta: n (%)
 Tenofovir 225 (97.8) 159 (99.4) 177 (98.3)
 Zidovudine 4 (1.7) 1 (0.6) 3 (1.7)
 Stavudine 1 (0.4)
 HADS depression score of 8 or above (borderline or case)b: n (%) 74 (32.1) 55 (34.3) 58 (32.2)
 HADS anxiety score of 8 or above (borderline or case)b: n (%) 89 (38.7) 64 (40.0) 70 (38.9)
 Non-disclosure: n (%) 11 (4.7) 8 (5.0) 7 (3.9)
 CAGE score ≥ 2: n (%) 35 (15.2) 22 (13.8) 25 (13.9)
  1. aAll were taking 3TC or FTC as a second NRTI
  2. b14-question Hospital Anxiety and Depression Score